Trump's Son-In-Law Back In Political Arena? Jared Kushner Reportedly Making Calls To Potential Donors To Attend Ex-President's New York Fundraiser For 2024 Run

Unsubscribe       This Little-known NASDAQ Company is Working on a Revolutionary "Wonder Drug" to Fight Alzheimer's, Secondary Progressive Multiple Sclerosis, ALS, and Other Neuroinflammatory Diseases.   The demand for treating neuroinflammatory diseases such as Alzheimer's and MS continues to grow. One company aims to bring to market a unique drug candidate that could significantly help millions of people suffering from such diseases. The cogs are in motion and the company is working diligently to be successful with its lead candidate Foralumab. Lead candidate, intranasal Foralumab, is the World's ONLY fully human anti-CD3 mAb!  How significant is anti-CD3 mAb?  Well, last year , Sanofi acquired Provention Bio for a staggering $2.9 billion for the company's humanized anti-CD3 monoclonal antibody drug, teplizumab. This company's lead candidate Foralumab has demonstrated a favorable safety profile and clinical response in patients in studies to date. Not long ago the company had exciting news, announcing that it has submitted an FDA request to obtain an Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation!    Discover why Foralumab is quickly gaining recognition across the scientific community and how it could build value for TLSA shareholders!

This email was sent to diansastroxz.forex@blogger.com by editor@dailymarketalerts.com DailyMarketAlerts c/o CLM Media LLC, 315 Ridgedale Avenue, #556, East Hanover, NJ 07936 United States    Unsubscribe | Report Spam